Mraz Amerine Associates Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Mraz Amerine Associates reduced its stake in Abbott Laboratories by 0.56% during the most recent quarter end. The investment management company now holds a total of 34,194 shares of Abbott Laboratories which is valued at $1,493,252 after selling 193 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Abbott Laboratories makes up approximately 0.52% of Mraz Amerine Associates’s portfolio.

Other Hedge Funds, Including , Country Club Trust Company N.a. reduced its stake in ABT by selling 400 shares or 5.23% in the most recent quarter. The Hedge Fund company now holds 7,244 shares of ABT which is valued at $312,723. Abbott Laboratories makes up approx 0.04% of Country Club Trust Company N.a.’s portfolio.Laurel Grove Capital reduced its stake in ABT by selling 12,800 shares or 29.96% in the most recent quarter. The Hedge Fund company now holds 29,925 shares of ABT which is valued at $1,291,862. Abbott Laboratories makes up approx 0.75% of Laurel Grove Capital’s portfolio. First United Bank Trust sold out all of its stake in ABT during the most recent quarter. The investment firm sold 4,838 shares of ABT which is valued $203,051.

Abbott Laboratories opened for trading at $44.38 and hit $45.12 on the upside on Friday, eventually ending the session at $44.75, with a gain of 0.67% or 0.3 points. The heightened volatility saw the trading volume jump to 1,34,23,155 shares. Company has a market cap of $65,745 M.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.